Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease.

Authors :: Cohen, A.D.
Luger, S.M.
Sickles, C.
Mangan, P.A.
Porter, D.L.
Schuster, S.J.
Tsai, D.E.
Nasta, S.
Gewirtz, A.M.
Stadtmauer, E.A.
Source :: Bone Marrow Transplantation. 7/1/2002, Vol. 30 Issue 1, p23. 6p. 2 Charts.
Publication Year :: 2002
Abstract: Studies the incidence of hepatic veno-occlusive disease of gemtuzumab ozogamicin monotherapy and its efficacy for relaped acute myeloid leukaemia after hematopoietic stem cell transplant. Methodology; Results of the study; Discussion of findings.

Subjects :: *DRUG therapy
*MYELOID leukemia
*STEM cells
*TRANSPLANTATION of organs, tissues, etc.

Full Text Access

Tools